Comparison of cerebrospinal fluid biomarkers in patients with severe COVID-19 neurological outcomes and Alzheimer’s disease

Collectively, our findings reveal that CSF tau levels are comparably elevated in COVID-19 neurological patients and AD, suggesting ongoing neurodegeneration in COVID-19 neurological disease, but no biomarker alterations related to AD pathology. Furthermore, CNS AD-related biomarker levels in COVID-19 patients change in association with disease severity and systemic inflammation. Considering that inflammation may persist post-COVID, our findings urge the assessment of possible AD-related biomarker changes in COVID-19 survivors with lingering symptoms.

Authors

Institutions

Publication Details

Journal
Brain Behavior & Immunity - Health
Published
2025-05-01
DOI
https://doi.org/10.1016/j.bbih.2025.101007
Citations
1
Primary Topic
Long-Term Effects of COVID-19
Type
article
Field-Weighted Citation Impact
1.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparison of cerebrospinal fluid biomarkers in patients with severe COVID-19 neurological outcomes and Alzheimer’s disease

Fernanda G. Q. Barros‐Aragão, TC Pinheiro, Fernanda G. De Felice, Andrea Silveira de Souza et al.
1 citations
Brain Behavior & Immunity - Health
Long-Term Effects of COVID-19
1.39
article

Comparison of cerebrospinal fluid biomarkers in patients with severe COVID-19 neurological outcomes and Alzheimer’s disease

Fernanda G. Q. Barros‐Aragão, TC Pinheiro, Fernanda G. De Felice, Andrea Silveira de Souza, Gabriel R. de Freitas, Felipe Kenji Sudo, Talita P. Pinto, Érika C. Rodrigues, Fernanda Tovar‐Moll, Bart Vanderborgh, Fernando A. Bozza, Guilherme B. de Freitas, Nathane Rezende, Paulo Mattos, Carlos Otávio Brandão
article en
1 citations

Abstract

Collectively, our findings reveal that CSF tau levels are comparably elevated in COVID-19 neurological patients and AD, suggesting ongoing neurodegeneration in COVID-19 neurological disease, but no biomarker alterations related to AD pathology. Furthermore, CNS AD-related biomarker levels in COVID-19 patients change in association with disease severity and systemic inflammation. Considering that inflammation may persist post-COVID, our findings urge the assessment of possible AD-related biomarker changes in COVID-19 survivors with lingering symptoms.

Brain Behavior & Immunity - HealthVol. 46
Universidade Federal do Rio de Janeiro (BR), Queen's University (CA), D’Or Institute for Research and Education (BR)
Instituto D'Or de Pesquisa e Ensino, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Ministério da Saúde
Good health and well-being
Openalex Percentile: Top 21%
Long-Term Effects of COVID-19
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.